NERV - Minerva Neurosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Minerva Neurosciences, Inc.

1601 Trapelo Road
Suite 284
Waltham, MA 02451
United States
617-600-7373
http://www.minervaneurosciences.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedAge
Dr. R�my LuthringerChief Exec. Officer and Director680.15kN/A56
Mr. Geoffrey Robin Race FCMA, MBAExec. VP, CFO & Chief Bus. Officer588.15kN/A56
Mr. Joseph ReillySr. VP & COO461kN/A42
Mr. Richard RussellPresN/AN/AN/A
Mr. Frederick W. Ahlholm CPASr. VP & Chief Accounting OfficerN/AN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The company' preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Corporate Governance

Minerva Neurosciences, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.